Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03370133
Registration number
NCT03370133
Ethics application status
Date submitted
7/12/2017
Date registered
12/12/2017
Date last updated
5/01/2024
Titles & IDs
Public title
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Query!
Scientific title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Query!
Secondary ID [1]
0
0
2016-003425-42
Query!
Secondary ID [2]
0
0
PS0009
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
BE VIVID
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Chronic Plaque Psoriasis
0
0
Query!
Moderate to Severe Chronic Plaque Psoriasis
0
0
Query!
Psoriatic Arthritis
0
0
Query!
Condition category
Condition code
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Musculoskeletal
0
0
0
0
Query!
Other muscular and skeletal disorders
Query!
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Bimekizumab
Treatment: Drugs - Ustekinumab
Other interventions - Placebo
Experimental: Bimekizumab cohort - Subjects will receive bimekizumab for 52 weeks.
Active Comparator: Ustekinumab cohort - Subjects will receive ustekinumab (dose 1 or dose 2 depending on subjects weight) for 52 weeks. Placebo will be administered at pre-specified time points to maintain the blinding.
Placebo Comparator: Placebo - Subjects will receive placebo up to week 16 and bimekizumab starting at week 16 through week 52.
Treatment: Drugs: Bimekizumab
Bimekizumab will be provided at pre-specified time intervals.
Treatment: Drugs: Ustekinumab
Ustekinumab will be provided as dose 1 for subjects weighing <=100 kg and as dose 2 for subjects weighing >100 kg at pre-specified time intervals.
Other interventions: Placebo
Subjects will receive Placebo at pre-specified time points.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16
Query!
Assessment method [1]
0
0
The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.
Query!
Timepoint [1]
0
0
Week 16
Query!
Primary outcome [2]
0
0
Percentage of Participants With an Investigator's Global Assessment (IGA) (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 16
Query!
Assessment method [2]
0
0
The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response was defined as clear [0] or almost clear [1] with at least a two-category improvement from Baseline at Week 16.
Query!
Timepoint [2]
0
0
Week 16
Query!
Secondary outcome [1]
0
0
Percentage of Participants With a PASI100 Response at Week 16
Query!
Assessment method [1]
0
0
The PASI100 response assessments are based on a 100% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.
Query!
Timepoint [1]
0
0
Week 16
Query!
Secondary outcome [2]
0
0
Percentage of Participants With an IGA 0 Response at Week 16
Query!
Assessment method [2]
0
0
The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response was defined as clear [0] with at least a two-category improvement from Baseline at Week 16.
Query!
Timepoint [2]
0
0
Week 16
Query!
Secondary outcome [3]
0
0
Percentage of Participants With a PASI75 Response at Week 4
Query!
Assessment method [3]
0
0
The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.
Query!
Timepoint [3]
0
0
Week 4
Query!
Secondary outcome [4]
0
0
Percentage of Participants With a Patient Symptom Diary Response for Pain at Week 16
Query!
Assessment method [4]
0
0
As Patient-Reported-Outcome (PRO) measure, the PSD (further published as P-SIM) was used to assess key symptoms relevant to patients with moderate to severe plaque psoriasis. Site staff trained participants on the use of the electronic device used to collect ePRO diary data at Screening, device was then dispensed to the participant for home use until Week 16 Visit. The ePRO diary was completed on daily basis from Screening to Week 16 Visit.
PSD pain item was assessed daily on a numeric rating scale (NRS) from 0 (no pain) to 10 (very severe pain). PSD score for pain at a given visit was an average of daily values over the week prior to the visit. The response was defined as an improvement (decrease) in pain score higher than the prespecified 1.98 response threshold at Week 16. The endpoint was characterized as percentage of participants with PSD pain response.
Query!
Timepoint [4]
0
0
Week 16
Query!
Secondary outcome [5]
0
0
Percentage of Participants With a Patient Symptom Diary Response for Itch at Week 16
Query!
Assessment method [5]
0
0
A PRO measure, the PSD (further published as P-SIM) was used to assess key symptoms relevant to patients with moderate to severe plaque psoriasis. Site staff trained participants on the use of the electronic device used to collect ePRO diary data at Screening, device was then dispensed to participant for home use until Week 16 Visit. The ePRO diary was completed on daily basis from Screening to Week 16 Visit.
PSD itch item was assessed daily on a NRS from 0 (no itch) to 10 (very severe itch). PSD score for itch was an average of daily values over the week prior to the visit. The response was defined as an improvement (decrease) in itch score higher than the prespecified 2.39 response threshold at Week 16. The endpoint was characterized as percentage of participants with a PSD itch response.
Query!
Timepoint [5]
0
0
Week 16
Query!
Secondary outcome [6]
0
0
Percentage of Participants With a Patient Symptom Diary Response for Scaling at Week 16
Query!
Assessment method [6]
0
0
As PRO measure, the PSD (further published as P-SIM) was used to assess key symptoms relevant to patients with moderate to severe plaque psoriasis. Site staff trained participants on the use of the electronic device used to collect ePRO diary data at Screening, device was then dispensed to the participant for home use until Week 16 Visit. The ePRO diary was completed on daily basis from Screening to Week 16 Visit. PSD scaling item was assessed daily on a NRS from 0 (no scaling) to 10 (very severe scaling). PSD score for scaling was an average of daily values over the week prior to the visit. The response was defined as an improvement (decrease) in scaling score higher than the prespecified 2.86 response threshold at Week 16. The endpoint was characterized as percentage of participants with a PSD scaling response.
Query!
Timepoint [6]
0
0
Week 16
Query!
Secondary outcome [7]
0
0
Percentage of Participants With a Scalp IGA Response (Clear or Almost Clear) at Week 16 for Participants With Scalp Psoriasis (PSO) >=2 at Baseline
Query!
Assessment method [7]
0
0
Only participants with scalp involvement at Baseline completed the scalp IGA. Participants with scalp involvement at Baseline were defined as those with a scalp IGA score >0 at Baseline. Scalp lesions were assessed in terms of clinical signs of redness, thickness, and scaliness using a 5-point scale (0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, 4= Severe). Scalp IGA 0/1 response at Week 16 was defined as clear (0) or almost clear (1) with at least a 2-category improvement from Baseline to Week 16.
Query!
Timepoint [7]
0
0
Week 16
Query!
Secondary outcome [8]
0
0
Percentage of Participants With a PASI90 Response at Week 12
Query!
Assessment method [8]
0
0
The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.
Query!
Timepoint [8]
0
0
Week 12
Query!
Secondary outcome [9]
0
0
Percentage of Participants With a PASI90 Response at Week 52
Query!
Assessment method [9]
0
0
The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.
Query!
Timepoint [9]
0
0
Week 52
Query!
Secondary outcome [10]
0
0
Percentage of Participants With an IGA (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 12
Query!
Assessment method [10]
0
0
The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response was defined as clear [0] or almost clear [1] with at least a two-category improvement from Baseline at Week 12.
Query!
Timepoint [10]
0
0
Week 12
Query!
Secondary outcome [11]
0
0
Percentage of Participants With an IGA (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) Response at Week 52
Query!
Assessment method [11]
0
0
The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response was defined as clear [0] or almost clear [1] with at least a two-category improvement from Baseline at Week 52.
Query!
Timepoint [11]
0
0
Week 52
Query!
Secondary outcome [12]
0
0
Number of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Study Treatment During the Initial Treatment Period
Query!
Assessment method [12]
0
0
The number of TEAEs adjusted by duration of exposure to study treatment was scaled such that provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the Adverse Event (AE) being considered. If a participant had no events, the total time at risk was used.
Query!
Timepoint [12]
0
0
From Baseline to end of Initial Treatment Period, including the Safety Follow-Up visit for those withdrawn from IMP (up to 36 weeks)
Query!
Secondary outcome [13]
0
0
Number of Serious Adverse Events (SAEs) Adjusted by Duration of Subject Exposure to Study Treatment During the Initial Treatment Period
Query!
Assessment method [13]
0
0
The number of SAEs adjusted by duration of exposure to study treatment was scaled such that it provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
Query!
Timepoint [13]
0
0
From Baseline to end of Initial Treatment Period, including the Safety Follow-Up visit for those withdrawn from IMP (up to 36 weeks)
Query!
Secondary outcome [14]
0
0
Number of TEAEs Leading to Withdrawal Adjusted by Duration of Subject Exposure to Study Treatment During the Initial Treatment Period
Query!
Assessment method [14]
0
0
The number of TEAEs leading to discontinuation adjusted by duration of exposure to study treatment was scaled such that it provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
Query!
Timepoint [14]
0
0
From Baseline to end of Initial Treatment Period, including the Safety Follow-Up visit for those withdrawn from IMP (up to 36 weeks)
Query!
Secondary outcome [15]
0
0
Number of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Study Treatment During the Maintenance Treatment Period
Query!
Assessment method [15]
0
0
The number of TEAEs adjusted by duration of exposure to study treatment was scaled such that it provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the Adverse Event (AE) being considered. If a participant had no events, the total time at risk was used.
Query!
Timepoint [15]
0
0
From Week 16 to Safety Follow-Up (up to 52 weeks duration)
Query!
Secondary outcome [16]
0
0
Number of Serious Adverse Events (SAEs) Adjusted by Duration of Subject Exposure to Study Treatment During the Maintenance Treatment Period
Query!
Assessment method [16]
0
0
The number of SAEs adjusted by duration of exposure to study treatment was scaled such that it provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
Query!
Timepoint [16]
0
0
From Week 16 to Safety Follow-Up (up to 52 weeks duration)
Query!
Secondary outcome [17]
0
0
Number of TEAEs Leading to Withdrawal Adjusted by Duration of Subject Exposure to Study Treatment During the Maintenance Treatment Period
Query!
Assessment method [17]
0
0
The number of TEAEs leading to discontinuation adjusted by duration of exposure to study treatment was scaled such that it provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
Query!
Timepoint [17]
0
0
From Week 16 to Safety Follow-Up (up to 52 weeks duration)
Query!
Eligibility
Key inclusion criteria
- Must be at least 18 years of age
- Chronic plaque psoriasis (PSO) for at least 6 months prior to the Screening Visit
- Psoriasis Area Severity Index (PASI) >=12 and body surface area (BSA) affected by PSO
>=10% and Investigator's Global Assessment (IGA) score >=3 on a 5-point scale
- Subject is a candidate for systemic PSO therapy and/or phototherapy
- Female subject of child bearing potential must be willing to use highly effective
method of contraception
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Subject has an active infection (except common cold), a recent serious infection, or a
history of opportunistic or recurrent chronic infections
- Subject has concurrent acute or chronic viral hepatitis B or C or human
immunodeficiency virus (HIV) infection
- Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB
infection, or has current or history of nontuberculous mycobacterium (NTMB) infection
- Subject has any other condition, including medical or psychiatric, which, in the
Investigator's judgment, would make the subject unsuitable for inclusion in the study
- Presence of active suicidal ideation or positive suicide behavior
- Presence of moderately severe major depression or severe major depression
- Subject has any active malignancy or history of malignancy within 5 years prior to the
Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell
carcinoma, or in situ cervical cancer
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
6/12/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
13/12/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
567
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Ps0009 004 - Fremantle
Query!
Recruitment hospital [2]
0
0
Ps0009 005 - Phillip
Query!
Recruitment hospital [3]
0
0
Ps0009 002 - Westmead
Query!
Recruitment hospital [4]
0
0
Ps0009 009 - Woolloongabba
Query!
Recruitment postcode(s) [1]
0
0
- Fremantle
Query!
Recruitment postcode(s) [2]
0
0
- Phillip
Query!
Recruitment postcode(s) [3]
0
0
- Westmead
Query!
Recruitment postcode(s) [4]
0
0
- Woolloongabba
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Indiana
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Iowa
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kansas
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Louisiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Michigan
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Missouri
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Nebraska
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New Hampshire
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New Jersey
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New Mexico
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New York
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Oregon
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Texas
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Bruxelles
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Liège
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Loverval
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Halifax
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Oakville
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
Richmond Hill
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Surrey
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Toronto
Query!
Country [26]
0
0
Canada
Query!
State/province [26]
0
0
Waterloo
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Bonn
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Darmstadt
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Erlangen
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Frankfurt/Main
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Friedrichshafen
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Hamburg
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Heidelberg
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Mahlow
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Osnabrück
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Schweinfurt
Query!
Country [37]
0
0
Hungary
Query!
State/province [37]
0
0
Budapest
Query!
Country [38]
0
0
Hungary
Query!
State/province [38]
0
0
Orosháza
Query!
Country [39]
0
0
Hungary
Query!
State/province [39]
0
0
Szekszárd
Query!
Country [40]
0
0
Italy
Query!
State/province [40]
0
0
Roma
Query!
Country [41]
0
0
Japan
Query!
State/province [41]
0
0
Asahikawa
Query!
Country [42]
0
0
Japan
Query!
State/province [42]
0
0
Bunkyo-Ku
Query!
Country [43]
0
0
Japan
Query!
State/province [43]
0
0
Chiyoda
Query!
Country [44]
0
0
Japan
Query!
State/province [44]
0
0
Chuo Ku
Query!
Country [45]
0
0
Japan
Query!
State/province [45]
0
0
Fukuoka
Query!
Country [46]
0
0
Japan
Query!
State/province [46]
0
0
Gifu
Query!
Country [47]
0
0
Japan
Query!
State/province [47]
0
0
Hamamatsu
Query!
Country [48]
0
0
Japan
Query!
State/province [48]
0
0
Itabashi-Ku
Query!
Country [49]
0
0
Japan
Query!
State/province [49]
0
0
Kobe
Query!
Country [50]
0
0
Japan
Query!
State/province [50]
0
0
Kurume
Query!
Country [51]
0
0
Japan
Query!
State/province [51]
0
0
Matsumoto
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Minato-Ku
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Morioka
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Nagoya
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Nankoku
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Obihiro
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Osaka
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Sapporo
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Sendai
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Shimotsuke
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Shinagawa-Ku
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Shinjuku-Ku
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Sumida
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Takaoka
Query!
Country [65]
0
0
Japan
Query!
State/province [65]
0
0
Tsu
Query!
Country [66]
0
0
Poland
Query!
State/province [66]
0
0
Bialystok
Query!
Country [67]
0
0
Poland
Query!
State/province [67]
0
0
Bydgoszcz
Query!
Country [68]
0
0
Poland
Query!
State/province [68]
0
0
Katowice
Query!
Country [69]
0
0
Poland
Query!
State/province [69]
0
0
Kielce
Query!
Country [70]
0
0
Poland
Query!
State/province [70]
0
0
Poznan
Query!
Country [71]
0
0
Poland
Query!
State/province [71]
0
0
Warsaw
Query!
Country [72]
0
0
Poland
Query!
State/province [72]
0
0
Wroclaw
Query!
Country [73]
0
0
Poland
Query!
State/province [73]
0
0
Lódz
Query!
Country [74]
0
0
Russian Federation
Query!
State/province [74]
0
0
Moscow
Query!
Country [75]
0
0
Russian Federation
Query!
State/province [75]
0
0
Saint Petersburg
Query!
Country [76]
0
0
United Kingdom
Query!
State/province [76]
0
0
Cardiff
Query!
Country [77]
0
0
United Kingdom
Query!
State/province [77]
0
0
Dundee
Query!
Country [78]
0
0
United Kingdom
Query!
State/province [78]
0
0
Edgbaston
Query!
Country [79]
0
0
United Kingdom
Query!
State/province [79]
0
0
Liverpool
Query!
Country [80]
0
0
United Kingdom
Query!
State/province [80]
0
0
Manchester
Query!
Country [81]
0
0
United Kingdom
Query!
State/province [81]
0
0
Salford
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
UCB Biopharma SRL
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a study to compare the efficacy of bimekizumab versus placebo and an active
comparator in the treatment of subjects with moderate to severe chronic plaque psoriasis
(PSO).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03370133
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
UCB Cares
Query!
Address
0
0
001 844 599 2273 (UCB)
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03370133
Download to PDF